BI 1291583: a novel selective inhibitor of cathepsin C with superior in vivo profile for the treatment of bronchiectasis

ConclusionBI 1291583-mediated inhibition of CatC is expected to restore the protease –antiprotease balance in the lungs of patients with chronic airway inflammatory diseases such as bronchiectasis.

Source: Inflammation Research - August 4, 2023 Category: Research Source Type: research